Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we cut back on bladder drugs for seniors? new study aims to find out

NCT ID NCT06110975

Knowledge-focused Sponsor: Anne Estrup Olesen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a guideline designed to help doctors safely reduce or stop overactive bladder medications in people aged 65 and older. Researchers will compare how many patients continue these drugs after six months between those whose doctors follow the guideline and those who receive usual care. The goal is to see if deprescribing can be done effectively in general practice without harming patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
deprescribing guideline (procedure)
What this could lead to
If successful, this could provide a safe way to reduce unnecessary medications for overactive bladder in older adults, improving quality of life and reducing side effects.
What could go wrong
This is a small, early-stage study (72 participants) testing a process, not a new drug. The approach may not work for everyone or may not be adopted widely in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 to 95 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patient must have been prescribed one of the following drugs for OAB within the last 14 months * patient must be able to speak and understand Danish Exclusion Criteria: * too cognitively impaired to participate or otherwise unfit to participate as estimated by general practitioner * receiving neurological or urogenital ambulatory care for their overactive bladder symptoms

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Deprescribing are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19–associated multisystem inflammatory syndrome in children overactive bladder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Deprescribing Overactive bladder PIMS

Contacts and locations

Locations

  • Aalborg University Hospital

    Aalborg, Aalborg, 9000, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.